[ET Net News Agency, 25 June 2021] SinoMab BioScience Limited (03681) said the China
National Medical Products Administration of China (NMPA) has approved the Investigational
New Drug (IND) application of SN1011 for pemphigus vulgaris (PV).
SN1011 is the first Bruton's tyrosine kinase (BTK) known for the treatment of PV in
China with huge unmet clinical needs. The IND approval would enable the company to conduct
comprehensive clinical development programs for the treatment of PV in China. This would
be the second targeted indication of SN1011, following the approval of systemic lupus
erythematous (SLE) indication in August 2020. The first healthy subject had been
successfully dosed in Phase I clinical trial for SLE in Shanghai, China on 15 January
2021, and Phase I clinical trial is in good progress. (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03681 SINOMAB BIO-B
Nominal 
1.200 -0.020 (-1.639%) Others
25/06/2021 15:16
SinoMab Bio (03681) gets IND application approval
| Remark: | Real time quote last updated: 20/09/2024 11:06 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |